Authors' Reply: Questions Regarding the Analysis of Long-Term Outcomes in Nephrotic Syndrome

Affiliations

¹ National Registry of Rare Kidney Diseases, UK Kidney Association, Bristol, United Kingdom.
² Travere Therapeutics, Inc., San Diego, California.
³ JAMCO Pharma Consulting, Stockholm, Sweden.
⁴ Leicester General Hospital, University of Leicester, Leicester, United Kingdom.
⁵ Department of Renal Medicine, University of Edinburgh, Edinburgh, United Kingdom.
⁶ Department of Renal Medicine, University College London, London, United Kingdom.
⁷ Bristol Royal Hospital for Children, University of Bristol, Bristol, United Kingdom.

David Pitcher et al. J Am Soc Nephrol. 2025.

. 2025 Oct 1;36(10):2082-2083.

doi: 10.1681/ASN.0000000812. Epub 2025 Aug 1.

¹ National Registry of Rare Kidney Diseases, UK Kidney Association, Bristol, United Kingdom.
² Travere Therapeutics, Inc., San Diego, California.
³ JAMCO Pharma Consulting, Stockholm, Sweden.
⁴ Leicester General Hospital, University of Leicester, Leicester, United Kingdom.
⁵ Department of Renal Medicine, University of Edinburgh, Edinburgh, United Kingdom.
⁶ Department of Renal Medicine, University College London, London, United Kingdom.
⁷ Bristol Royal Hospital for Children, University of Bristol, Bristol, United Kingdom.

No abstract available

Keywords: glomerular disease; glomerular diseases; glomerulopathy; glomerulus; nephrotic syndrome.

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/F312.

1. Dai Z, Zhou F, Luo Q. Questions regarding the analysis of long-term outcomes in nephrotic syndrome. J Am Soc Nephrol. 2025;36(10):2080–2081. doi: 10.1681/ASN.0000000811 - DOI - PubMed
1. Pitcher D Braddon F Hendry B, et al. Long-term outcomes in nephrotic syndrome by kidney biopsy diagnosis and proteinuria. J Am Soc Nephrol. 2025;36(7):1398–1413. doi: 10.1681/ASN.0000000610 - DOI - PMC - PubMed